Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 8 art units • 11 examiners • 0 of 14 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sapreme Technologies B V operates within the Biotechnology & Pharmaceuticals technology area with a portfolio containing 13 pending office actions. This workload is distributed among 11 distinct examiners, suggesting a broad engagement with the patent office. The involvement of 8 distinct art units further indicates that the company's research and development efforts span multiple specialized sub-sectors.
ZARA, JANE J is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. While this examiner has the highest individual count, the presence of 11 distinct examiners means that most of the 13 pending actions are being reviewed by different officials. This distribution minimizes the impact of any single examiner's tendencies on the overall portfolio.
The presence of 8 distinct art units for 13 pending office actions shows some concentration of subject matter, though the presence of 11 distinct examiners relative to actions suggests a diverse prosecution landscape. Practitioners must coordinate strategies across these units to ensure consistency in the Biotechnology & Pharmaceuticals space. The reliance on 2 pending actions for the busiest examiner highlights the lack of central examiner control.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 4 (29%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 5 (36%) |
| Multi-statute (no §101) | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZARA, JANE J | 2 | 71.0% | +16.1% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| SKOKO III, JOHN JOSEPH | 2 | 53.1% | +58.2% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| HIBSHMAN, SARAH GRACE | 1 | 38.9% | +40.0% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| LEE, HOI YAN NMN | 1 | 38.4% | +75.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | HUYNH, PHUONG N | 22d |
| 18564885 | CYTOSOLIC DELIVERY OF GENOME EDITING TOOLS | SU-TOBON, QIWEN NMN | — |
| 18012760 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | HUYNH, PHUONG N | — |
| 17312104 | Saponin Conjugates | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 30d overdue |
| 18044945 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | CHONG, KIMBERLY | 9d overdue |
| 18012694 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | CREWS, JARET JAMES | 1d overdue |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | PUTTLITZ, KARL J | 14d |
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | HUYNH, PHUONG N | 22d |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 26d |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | LEE, HOI YAN NMN | 34d |
| 18564885 | CYTOSOLIC DELIVERY OF GENOME EDITING TOOLS | SU-TOBON, QIWEN NMN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 3 |
| 1637 | 2 |
| 1641 | 2 |
| 1643 | 2 |
| 1636 | 1 |
| 1646 | 1 |
| 1691 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564885 | CYTOSOLIC DELIVERY OF GENOME EDITING TOOLS | SU-TOBON, QIWEN NMN | — | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18044945 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | CHONG, KIMBERLY | 1636 | §103§112DP | Final Rejection | 9d overdue | Pending | Mar 10, 2023 |
| 18012769 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | ZARA, JANE J | 1637 | §112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18012791 | HYDRAZONE-BASED SAPONIN DERIVATIVES | HIBSHMAN, SARAH GRACE | 1693 | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | 14d | Pending | Dec 23, 2022 |
| 18012760 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | HUYNH, PHUONG N | 1641 | §103§112Other | Final Rejection | — | Pending | Dec 23, 2022 |
| 18012694 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 1d overdue | Pending | Dec 23, 2022 |
| 18012729 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CHO, DAVID H | 1693 | §103DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 18012754 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 1643 | §103Other | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 1643 | §103Other | Final Rejection | 26d | Pending | Dec 23, 2022 |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | LEE, HOI YAN NMN | 1693 | §103Other | Final Rejection | 34d | Pending | Jan 24, 2022 |
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 1637 | §103§112DP | Final Rejection | 30d overdue | Pending | Jun 18, 2021 |
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | HUYNH, PHUONG N | 1641 | §103§112Other | Final Rejection | 22d | Pending | Jun 09, 2021 |
| 17312104 | Saponin Conjugates | BAKSHI, PANCHAM | 1623 | §102§112 | Non-Final OA | — | Pending | Jun 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial